Heparin-induced Thrombocytopenia (HIT II) in Liver Transplant Recipients

Heparin-induced Thrombocytopenia (HIT II) in Liver Transplant Recipients: a Prospective Multivariate Analysis of Prognostic Factors and Haemostaseological Findings

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01654848

Acronym

HITOLT

Enrollment

Registered

2012-08-01

Start date

2010-01-31

Completion date

2011-08-31

Last updated

2012-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heparin-induced Thrombocytopenia, Liver Transplantation

Keywords

liver transplantation, thrombocytes, heparin-induced thrombocytopenia, multivariate analysis of associated factors of HIT 2 after OLT, laboratory investigations of HIT-antibodies

Brief summary

In a prospective observational study the incidence of Heparin-induced Thrombocytopenia (HIT) Type 2 after orthotopic liver transplantation, associated factors, and hemostaseological findings in thrombocytes and anti-body patterns is going to be investigated.

Detailed description

The investigators examined the frequency of anti-PF4/heparin antibodies (IgG/M/A; EIA) and their functional activity (HIPA) in 38 whole organ deceased donor liver transplant recipients. Additionally, demographic, clinical, donor- and recipient-specific parameters and laboratory findings (ALAT, ASAT, cholinesterase) were investigated.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* all consecutive liver transplant recipients between 01/2010 and 08/2011 who * were transplanted at our center after allocation of a liver graft via Eurotransplant

Exclusion criteria

* patient's refusal to participate in prospective observation

Countries

Germany

Outcome results